Trividia Health, Inc. v. Nipro Corporation

CourtDistrict Court, S.D. New York
DecidedDecember 10, 2021
Docket1:20-cv-08450
StatusUnknown

This text of Trividia Health, Inc. v. Nipro Corporation (Trividia Health, Inc. v. Nipro Corporation) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Trividia Health, Inc. v. Nipro Corporation, (S.D.N.Y. 2021).

Opinion

UNITED STATES DISTRICT COURT U DOSD CC U MSD EN NY T SOUTHERN DISTRICT OF NEW YORK ELECTRONICALLY FILED -------------------------------------------------------------- X DOC #: TRIVIDIA HEALTH, INC., : DATE FILED: 12/10 /21 : Petitioner, : : -against- : 20-CV-8450 (VEC) : NIPRO CORPORATION, : ORDER : Respondent. : -------------------------------------------------------------- X VALERIE CAPRONI, United States District Judge: On September 18, 2020, after an arbitration proceeding that spanned three years, an arbitral tribunal of the International Chamber of Commerce (“ICC”) issued a Final Award determining that Respondent Nipro Corporation (“Nipro”) had breached an agreement with Petitioner Trividia Health, Inc. (“Trividia”), and awarding Petitioner, taking into account the interest that has since accrued, $21,668,302.30 in damages and legal costs. McCawley Decl., Ex. A, Dkt. 2-1; Pet. ¶ 22, Dkt. 1. On October 9, 2020, Trividia moved to confirm the non-domestic arbitration award. See generally Pet., Dkt. 1. Nipro opposes the motion. See generally Resp. Opp., Dkt. 19. For the following reasons, Trividia’s petition is GRANTED, and the arbitration award is confirmed. BACKGROUND Trividia, a U.S.-based manufacturer of blood glucose monitoring systems and accessories, and Nipro, a Japanese corporation that distributes such system and accessories, entered into an International Distribution Agreement (“IDA”) on October 27, 2015. The IDA included an arbitration clause.1 See Pet. ¶¶ 1–2, 6–7. The IDA required Nipro to purchase from Trividia minimum quantities of blood glucose meter and test trip-related products for five years from the time of execution. McCawley Decl., Ex. A at 20. The parties disputed whether Nipro was required to make “annual minimum purchases” after the second year of the contract or whether it could terminate the contract at that point without incurring damages. Resp. Opp. at 3.

On February 27, 2018, after the parties negotiated unsuccessfully for the annual minimum purchase amount for the third year of the contract, Trividia requested arbitration; a three-person arbitral tribunal (the “Tribunal”) then began proceedings. Namura Decl., Ex. 1, Dkt. 20-1; Pet. ¶¶ 8–9. The Tribunal issued a Partial Final Award on October 16, 2018, determining that the agreement did not limit Trividia’s remedies for breach to a right to terminate the contract. Pet. ¶ 12. After further briefing and hearings, the Tribunal issued a Final Award on September 18, 2020, determining that Trividia was the prevailing party; that Nipro had breached the IDA by failing to make the annual minimum purchase during the third year of the contract; and that Nipro must pay Trividia what now comes to $21,668,302.30 in damages, prejudgment interest,

legal costs, and arbitration costs. Id. ¶¶ 20–22. Nipro has not yet paid the Final Award. Id. ¶ 24. DISCUSSION I. Legal Standard Under the Convention on the Recognition and Enforcement of Foreign Arbitral Awards (the “New York Convention”), 9 U.S.C. §§ 201 et seq., a district court shall confirm a non- domestic arbitral award “unless it finds one of the grounds for refusal or deferral of recognition or enforcement of the award specified in the said Convention.” 9 U.S.C. § 207. Those grounds include: (a) the agreement is not valid under the law or a party was under some incapacity; (b)

1 Trividia was formerly Nipro Diagnostics, Inc., a subsidiary of Nipro. After it was acquired by Shenzhen Xinnuo Health Industry Investment Ltd. it changed its name to Trividia. Resp. Opp., Dkt. 19 at 3. the party against whom the award is invoked was not given proper notice of the arbitration; (c) the award deals with a difference not contemplated by or not falling within the terms or scope of the submission to arbitration; (d) the composition of the arbitral authority or the procedure used does not follow the parties’ agreement; or (e) the award has not yet become binding on the parties or was otherwise set aside. Yusuf Ahmed Alghanim & Sons v. Toys “R” Us, Inc., 126

F.3d 15, 19 (2d Cir. 1997) (quoting art. V(1) of the Convention). Although the New York Convention provides the grounds for refusing to confirm a non- domestic arbitral award, the Federal Arbitration Act (the “FAA”), 9 U.S.C. §§ 1 et seq., provides another opportunity for vacatur if the non-domestic award was rendered in the United States. Toys “R” Us, Inc., 126 F.3d at 21.2 Under the FAA, a district court may vacate an arbitration award if: “(1) the award was procured by corruption, fraud, or undue means; (2) the arbitrators exhibited evident partiality or corruption; (3) the arbitrators were guilty of misconduct such as refusing to hear evidence pertinent and material to the controversy or any other misbehavior that prejudiced the rights of any party; or (4) the arbitrators exceeded their powers.” Pfeffer v. Wells

Fargo Advisors, LLC, 723 F. App’x 45, 47 (2d Cir. 2018) (quoting 9 U.S.C. § 10(a)) (citation and internal quotation marks omitted). The “party moving to vacate an arbitration award has the burden of proof, and the showing required to avoid confirmation is very high.” STMicroelectronics, N.V. v. Credit Suisse Sec. (USA) LLC, 648 F.3d 68, 74 (2d Cir. 2011) (quoting D.H. Blair & Co. v. Gottdiener, 462 F.3d 95, 110 (2d Cir. 2006)). Moreover, an arbitration award is granted significant deference by the court, and a court should enforce an award “if there is a barely colorable justification for the outcome reached.” Wallace v. Buttar, 378 F.3d 182, 190 (2d Cir. 2004) (citation and quotation marks omitted). A panel does not have

2 The Tribunal, constituted by the ICC, held all proceedings in New York City. Pet. ¶ 5. to explain the rationale behind its finding so long as the “ground[s] for the arbitrator’s decision can be inferred from the facts of the case.” Barbier v. Shearson Lehman Hutton Inc., 948 F.2d 117, 121 (2d Cir. 1991) (citation omitted). II. Nipro Was Not Deprived of Due Process Nipro asserts generally that it was deprived of due process throughout the arbitration

proceeding, in contravention of Article V(1)(b) of the New York Convention, which protects a party’s ability to present its case. Resp. Opp. at 1. Trividia counters that Nipro’s evidence of prejudice has been taken out of context. Pet. Reply, Dkt. 28 at 1. The Court addresses each of Nipro’s arguments in turn. A. Procedural Order of June 27, 2018 On June 27, 2018, the Tribunal issued a procedural order to guide the trajectory of the proceeding. See Namura Decl., Ex. 3, Dkt. 20-3. That order broadly required the parties to inform the Tribunal of all information relevant to the case, including factual allegations, legal arguments, and evidence. Id. at 3. Nipro argues that Trividia “flouted” this order. Resp. Opp. at

2.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Trividia Health, Inc. v. Nipro Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/trividia-health-inc-v-nipro-corporation-nysd-2021.